Stock ENDV ENDONOVO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages Endonovo Therapeutics, Inc. Other OTC

Equities

ENDV

US29272H3003

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Endonovo Therapeutics, Inc. Announces Final Stages to Receive Taiwan FDA License to Distribute in Taiwan
Endonovo Announces Distribution Agreement with Academy Medical
Endonovo Partners with International Distributor for SofPulse Line
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as A Listed Public Company
Endonovo Therapeutics, Inc. agreed to Spin-Off Medical Device Division of Endonovo Therapeutics.
Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical Expansion
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENDV Stock
  4. ENDV Stock
  5. News Endonovo Therapeutics, Inc.
  6. Other languages
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**Like the pros, access all the transcripts and spot the best opportunities before anyone else.**#ffffff**/services/solutions/**#004eff**#000000**Unlock them now!**1**